ReviewTheranostics2025
Mechanisms and novel therapeutic roles of bitter taste receptors in diseases.
Review in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bitter Chinese Herbal Medicine Exerts Pharmacological Effects via TAS2Rs: A Systematic Review from Natural Ligands to Therapeutic Potential.International journal of molecular sciences · 2026Pooled it
- Activation of Extraoral Bitter Taste Receptors by Herbs and Spices in the Regulation of Incretin Signaling and Glucose Metabolism.Nutrition reviews · 2026Review
- Article
- The possible renoprotective effect of denatonium benzoate in a rat model of type 2 diabetes: role of Krüppel-like factor 6 (KLF6).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Propionate attenuates osteoarthritis progression by regulating the gut-joint axis.Frontiers in immunology · 2026Article
- TAS2R38 taster variants-linked MGAM expression in Alzheimer's disease: a novel target for precision drug repurposing.Frontiers in aging neuroscience · 2026Article
- Biological Actions of Bile Acids via Cell Surface Receptors.International journal of molecular sciences · 2025Review
- Bitter taste receptors in the gut-vascular axis: a novel target for immune and metabolic regulation of hypertension.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bitter taste receptors (TAS2R) are expressed in the oral cavity, intestine, airways, and vascular smooth muscle, where they regulate physiological processes, including immune responses. However, the activation of TAS2R triggers signaling pathways that influence inflammation, metabolism, and cell proliferation, suggesting their potential as therapeutic targets for diseases such as Alzheimer's disease, Parkinson's disease, asthma, and cancer. Bitter compounds capable of activating TAS2R have shown potential in modulating these pathways, presenting novel opportunities for drug development. This review examines the expression of TAS2R across diverse tissues, their complex physiological roles, and potential therapeutic applications, including disease management and targeted drug delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.